Izumi Yotaro, Xu Lei, di Tomaso Emmanuelle, Fukumura Dai, Jain Rakesh K
Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Nature. 2002 Mar 21;416(6878):279-80. doi: 10.1038/416279b.
Malignant tumours secrete factors that enable them to commandeer their own blood supply (angiogenesis), and blocking the action of these factors can inhibit tumour growth. But because tumours may become resistant to treatments that target individual angiogenic factors by switching over to other angiogenic molecules, a cocktail of multiple anti-angiogenic agents should be more effective. Here we show that herceptin, a monoclonal antibody against the cell-surface receptor HER2 (for human epidermal growth factor receptor-2; ref. 4), induces normalization and regression of the vasculature in an experimental human breast tumour that overexpresses HER2 in mice, and that it works by modulating the effects of different pro- and anti-angiogenic factors. As a single agent that acts against multiple targets, herceptin, or drugs like it, may offer a simple alternative to combination anti-angiogenic treatments.
恶性肿瘤会分泌一些因子，使其能够征用自身的血液供应（血管生成），而阻断这些因子的作用可以抑制肿瘤生长。但是，由于肿瘤可能会通过转而使用其他血管生成分子而对针对单个血管生成因子的治疗产生抗性，因此多种抗血管生成药物的组合应该会更有效。我们在此表明，赫赛汀，一种针对细胞表面受体HER2（人表皮生长因子受体2；参考文献4）的单克隆抗体，可在实验性人乳腺肿瘤中诱导血管正常化和消退，该肿瘤在小鼠中过度表达HER2，并且它通过调节不同的促血管生成和抗血管生成因子的作用来发挥作用。作为一种针对多个靶点起作用的单一药物，赫赛汀或类似药物可能为联合抗血管生成治疗提供一种简单的替代方案。
